International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 3 , Pages 928-933, 1 July 2009

Radiation Response in Two HPV-Infected Head-and-Neck Cancer Cell Lines in Comparison to a Non–HPV-Infected Cell Line and Relationship to Signaling Through AKT

  • Anjali K. Gupta, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA
    • Corresponding Author InformationReprint requests to: Anjali K. Gupta, M.D., Department of Radiation Oncology, University of Iowa, Hospitals and Clinics, 200 Hawkins Drive, 1625 PFP LLWA, Iowa City, IA 52242. Tel: (319) 384-6135; Fax: (319) 356-1530
  • ,
  • John H. Lee, M.D.

      Affiliations

    • Sanford ENT-H&N Surgery, Sanford Cancer Research, Sioux Falls, SD
  • ,
  • Werner W. Wilke, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA
  • ,
  • Harry Quon, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
  • ,
  • Gareth Smith, B.A.

      Affiliations

    • Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA
  • ,
  • Amit Maity, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA
  • ,
  • John M. Buatti, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA
  • ,
  • Douglas R. Spitz, Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA

Received 18 November 2008; received in revised form 10 February 2009; accepted 2 March 2009.

Purpose

Human papilloma virus (HPV)-associated cancers of the head and neck (H&N) are increasing in frequency and are often treated with radiation. There are conflicting data in the literature regarding the radiation response in the presence of HPV infection, with some data suggesting they may be more sensitive to radiation. There are few studies looking at in vitro effects of HPV and further sensitization by inhibitors of specific signaling pathways. We are in the process of starting a clinical trial in H&N cancer patients using nelfinavir (NFV) (which inhibits Akt) and it would be important to know the effect of HPV on radiation response ± NFV.

Methods and Materials

Two naturally infected HPV-16 cell lines (UPCI-SCC90 and UMSCC47) and the HPV-negative SQ20B H&N squamous carcinoma cells were used. Western blots with or without 10 uM NFV were done to evaluate signaling from the PI3K-Akt pathway. Clonogenic assays were done in the three cell lines with or without NFV.

Results

Both UPCI-SCC90 and UMSCC47 cells were sensitive to radiation as compared with SQ20B and the degree corresponded to Akt activation. The SQ20B cell line has an activating mutation in EGFR resulting in phosphorylation (P) of Akt; UMSCC47 has decreased P-phosphatase and TENsin (PTEN), resulting in increased P-Akt; UPCI-SCC90 had overexpression of P-PTEN and decreased P-Akt. NFV resulted in downregulation of Akt in all three cell lines, resulting in sensitization to radiation.

Conclusions

HPV-infected H&N cancers are sensitive to radiation. The degree of sensitivity correlates to Akt activation and they can be further sensitized by NFV.

HPV, Radiation sensitization, Akt, Nelfinavir, PTEN

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by NIH grant R21 CA121580-01A1 (A.K.G.).

 Presented at 50th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Boston, MA, September 21–25, 2008.

 Anjali K. Gupta has a use patent pending on Nelfinavir as a radiation sensitizer. No other conflicts of interest to report.

PII: S0360-3016(09)00363-0

doi:10.1016/j.ijrobp.2009.03.004

International Journal of Radiation Oncology * Biology * Physics
Volume 74, Issue 3 , Pages 928-933, 1 July 2009